Kevin Reilly, Ally Bridge Group | theCUBE + NYSE Wired MedTech Unplugged Series

In this episode of the MedTech Unplugged series at the New York Stock Exchange, Kevin Reilly, managing director and head of MedTech at Ally Bridge Group, discusses the evolving landscape of medical technology from a private equity perspective. With a focus on deploying over $1.5 billion in capital toward life sciences and MedTech, Reilly highlights investment strategies centered on best-in-class technologies across various therapeutic areas including cardiovascular, neurovascular, robotics, and diagnostics. The conversation explores the impact of AI-enabled devices, regulatory challenges, the revival of the IPO market, and the growing importance of clinical data in shaping innovative healthcare solutions.

• Investment strategies of Ally Bridge Group in the MedTech space.
• The role of AI and supercomputing in transforming patient care.
• Challenges associated with FDA approvals and physician adoption.
• The thawing IPO market and recent successful exits like Kestra and Cervella.
• The importance of clinical data and patient-centric outcomes in innovation.
• Impact of chronic diseases and an aging population on growth segments.
• The intersection of robotics, software, and clinical data in MedTech.
• Future trends in MedTech, particularly in patient monitoring technologies.